Imaging of non-or very subtle contrast-enhancing malignant gliomas with [ 11C]-methionine positron emission tomography

Molecular Imaging

Volumn 10, Issue 6, 2011, Pages 453-459

  Galldiks, Norbert ^a,b,c   Kracht, Lutz W ^a,b,c   Dunkl, Veronika ^a,b,c   Ullrich, Roland T ^a,b,c   Vollmar, Stefan ^a,b,c   Jacobs, Andreas H ^a,b,c   Fink, Gereon R ^a,b,c   Schroeter, Michael ^a,b,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE PARTS; CONTRAST ENHANCEMENT; CONTRAST-ENHANCED; COREGISTRATION; GD-DTPA; METHIONINE POSITRON EMISSION TOMOGRAPHY; TREATMENT PLANNING; TUMOR TISSUES; TUMOR VOLUMES; VOLUME OF INTEREST ANALYSIS; WORLD HEALTH ORGANIZATION;

AMINO ACIDS; GADOLINIUM; MAGNETIC RESONANCE IMAGING; PATIENT TREATMENT; POSITRONS; TUMORS;

POSITRON EMISSION TOMOGRAPHY;

CARBON; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE; METHIONINE; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; FEMALE; GLIOMA; HUMAN; IMAGE ENHANCEMENT; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SCINTISCANNING;

ADULT; CARBON RADIOISOTOPES; FEMALE; GADOLINIUM DTPA; GLIOMA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; METHIONINE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 84855322162     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2011.00014     Document Type: Article

References (36)

1. Ginsberg LE, Fuller GN, Hashmi M, et al. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 1998;49:436-40, doi: 10.1016/S0090-3019(97) 00360-1. (Pubitemid 28153024)
2. Chamberlain MC, Murovic JA, Levin VA. Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology 1988;38:1371-4.
3. Perez-Cruet MJ, Adelman L, Anderson M, et al. CT-guided stereotactic biopsy of nonenhancing brain lesions. Stereotact Funct Neurosurg 1993;61:105-17, doi: 10.1159/000100629. (Pubitemid 24263827)
4. Perry JR, Tien RD, McLendon RE, et al. Argument for stereotactic biopsy of suspected low-grade glioma: results from 53 nonenhancing lesions. Neurology 1996;46: A158.
5. Barker FG 2nd, Chang SM, Huhn SL, et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 1997;80:936-41, doi: 10.1002/(SICI) 1097-0142(19971215) 80:12+ <2347::AID-CNCR3>3.0. CO;2-8. (Pubitemid 27360923)
6. Chaichana KL, Kosztowski T, Niranjan A, et al. Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults. J Neurosurg 2010;113:286-92, doi: 10.3171/2010.2. JNS 091010.
7. Landy HJ, Lee TT, Potter P, et al. Early MRI findings in high grade glioma. J Neurooncol 2000;47:65-72, doi: 10.1023/A:100649 4604527. (Pubitemid 30458408)
8. Berger G, Maziere M, Knipper R, et al. Automated synthesis of 11C-labelled radiopharmaceuticals: imipramine, chlorpromazine, nicotine and methionine. Int J Appl Radiat Isot 1979;30:393-9, doi: 10.1016/0020-708X(79) 90049-8. (Pubitemid 9238660)
9. Galldiks N, Ullrich R, Schroeter M, et al. Volumetry of [(11) C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging 2010;37:84-92, doi: 10.1007/s00259-009-1219-5.
10. 11C-Methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50:1316-22. (Pubitemid 28240345)
11. Vollmar S, Hampl J, Kracht L, Herholz K. Integration of functional data (PET) into brain surgery planning und neuronavigation. Springer Proc Phys 2007;114:98-103, doi: 10.1007/978-3-540-68764-1-16.
12. Kracht LW, Miletic H, Busch S, et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004;10:7163-70, doi: 10.1158/1078-0432. CCR-04-0262. (Pubitemid 39487701)
13. 11C-methionine positron emission tomography for glioma. Neuroimage 2009;45:312-8, doi: 10.1016/j.neuroimage.2008.11.034.
14. 11C- methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 2006;33:516-24, doi: 10.1007/s00259-005- 0002-5.
15. Cizek J, Herholz K, Vollmar S, et al. Fast and robust registration of PET and MR images of human brain. Neuroimage 2004;22:434-42, doi: 10.1016/j.neuroimage.2004.01.016. (Pubitemid 38515852)
16. Lunsford LD, Martinez AJ, Latchaw RE. Magnetic resonance imaging does not define tumor boundaries. Acta Radiol Suppl 1986;369:154-6.
17. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusionweighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53-60, doi: 10.1002/(SICI) 1522-2586(199901) 9:1<53::AID-JMRI7>3.0. CO;2-2. (Pubitemid 29068231)
18. Pauleit D, Langen KJ, Floeth F, et al. Can the apparent diffusion coefficient be used as a noninvasive parameter to distinguish tumor tissue from peritumoral tissue in cerebral gliomas? J Magn Reson Imaging 2004;20:758-64, doi: 10.1002/jmri.20177. (Pubitemid 39426069)
19. Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imagingdetermined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998;6:1479-86. (Pubitemid 28531609)
20. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41-51.
21. Maia AC Jr, Malheiros SM, da Rocha AJ, et al. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 2005;26:777-83. (Pubitemid 43079767)
22. Hakyemez B, Erdogan C, Bolca N, et al. Evaluation of different cerebral mass lesions by perfusion-weighted MR imaging. J Magn Reson Imaging 2006;24:817-24, doi: 10.1002/jmri.20707. (Pubitemid 44549984)
23. Kim do K, Kanai Y, Choi HW, et al. Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochim Biophys Acta 2002 1565. 112-21.
24. Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432-45. (Pubitemid 32207394)
25. Bustany P, Chatel M, Derlon JM, et al. Brain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with C11-L-methionine. J Neurooncol 1986;3:397-404, doi: 10.1007/BF00165590. (Pubitemid 16128633)
26. Lilja A, Bergstrom K, Hartvig P, et al. Dynamic study of supratentorial gliomas with L-methyl-11C-methionine and positron emission tomography. AJNR Am J Neuroradiol 1985;6:505-14. (Pubitemid 15070032)
27. 11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas. Zentralbl Neurochir 2007;68:19-23, doi: 10.1055/s-2007-970601. (Pubitemid 46745004)
28. Roessler K, Gatterbauer B, Becherer A, et al. Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation. Minim Invasive Neurosurg 2007;50:273-80, doi: 10.1055/s-2007-991143.
29. 11C-methyl)- L-methionine uptake index. Neurol Med Chir (Tokyo) 1990;30:997-1002, doi: 10.2176/nmc.30.997.
30. Kelly PJ, Daumas-Duport C, Scheithauer BW, et al. Stereotactic histologic correlations of computed tomography-and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987;62:450-9. (Pubitemid 17084816)
31. 11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:64-74, doi: 10.1016/j.ijrobp. 2005.01.045. (Pubitemid 41583543)
32. 11C-Methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:339-44, doi: 10.1016/j.ijrobp. 2006.02.047. (Pubitemid 44332720)
33. Mahasittiwat P, Mizoe JE, Hasegawa A, et al. L-[METHYL-(11) C] methionine positron emission tomography for target delineation in malignant gliomas: impact on results of carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:515-22, doi: 10.1016/j.ijrobp. 2007.06.071.
34. Pirotte BJ, Levivier M, Goldman S, et al. Positron emission tomography-guided volumetric resection of supratentorial highgrade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery 2009;64:471-81; discussion 81, doi: 10.1227/01. NEU.0000338949.94496.85.
35. Pauleit D, Floeth F, Hamacher K, et al. O-(2-[18F]Fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005;128:678-87, doi: 10.1093/brain/awh399. (Pubitemid 40380202)
36. Plotkin M, Blechschmidt C, Auf G, et al. Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrastenhancing gliomas. Eur Radiol 2010;20:2496-502, doi: 10.1007/s00330-010-1819-2.